Is NCT06780085 recruiting in Lexington, KY?

Yes, NCT06780085 is currently recruiting participants at its Lexington, KY location. This non-small cell lung cancer clinical trial is actively enrolling qualified participants.

How do I join the non-small cell lung cancer clinical trial in Lexington?

To join this clinical trial in Lexington, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Lexington clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Non-small Cell Lung Cancer Clinical Trial in Lexington, KY

About This Non-small Cell Lung Cancer Study in Lexington

Researchers are looking for new ways to treat metastatic nonsquamous non-small cell lung cancer (NSCLC) that has been treated before. Metastatic means the cancer has spread to other parts of the body. Nonsquamous means the cancer did not start in squamous cells, which are flat cells that line the inside of the lungs. Standard treatment (usual treatment) for NSCLC is surgery, then immunotherapy with or without chemotherapy after surgery. Immunotherapy is a treatment that helps the immune system

Sponsor: Merck Sharp & Dohme LLC

Who Can Participate

Inclusion Criteria

The main inclusion criteria include but are not limited to the following:

Histologically or cytologically confirmed diagnosis of Stage IV nonsquamous non-small cell lung cancer (NSCLC)

Documented disease progression per RECIST 1.1 after receiving an anti-programmed cell death 1 protein (PD-1)/programmed cell death ligand 1 (PD-L1) treatment and platinum-based chemotherapy

Confirmation per local test report that epidermal growth factor receptor negative (EGFR-), anaplastic lymphoma kinase negative (ALK-), c ros oncogene 1 negative (ROS1-), or other directed therapy is not indicated as primary therapy

Measurable disease per RECIST 1.1 as assessed by investigator and verified by BICR

Life expectancy of at least 3 months

An Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 assessed within 7 days before randomization

Is an individual of any sex/gender who is at least 18 years of age at the time of providing the informed consent

Has adequate organ function

If capable of producing sperm refrains from donating sperm plus either abstains from penile-vaginal intercourse or uses a penile/external condom, with contraceptive use consistent with local regulations

Participant/participants of childbearing potential (POCBP) is not pregnant and has a negative highly sensitive pregnancy test; and is not breastfeeding and uses a highly effective contraceptive method

Archival tumor tissue sample of a tumor lesion not previously irradiated has been provided

Has provided tissue prior to treatment randomization from a newly obtained formalin-fixed sample from a new biopsy

Human Immunodeficiency Virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy (ART)

Participants who are hepatitis B surface antigen (HBsAg) positive have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to randomization

Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening

Exclusion Criteria

The main exclusion criteria include but are not limited to the following:

Diagnosis of small cell lung cancer or, for mixed tumors, presence of small cell elements

Received radiation therapy to the lung

Has uncontrolled or significant cardiovascular disorder prior to randomization

Has clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses

Participants who have adverse events (AEs) (other than alopecia) due to previous anticancer therapies must have recovered to ≤Grade 1 or baseline

Has known severe hypersensitivity (≥Grade 3) to study intervention and/or any of its excipients

Has clinically significant corneal disease

Has received prior radiotherapy within 2 weeks of start of study intervention, or radiation related toxicities, requiring corticosteroids

Has inadequate washout period prior to randomization

Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention

Has diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy

Has previously received docetaxel as monotherapy or in combination with other therapies

Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration

Has known additional malignancy that is progressing or has required active treatment within the past 3 years

Has known untreated central nervous system (CNS) metastases and/or carcinomatous meningitis

Has evidence of any leptomeningeal disease

Has history of interstitial lung disease (ILD)/pneumonitis, current diagnosis of ILD, and/or suspected ILD

Has active autoimmune disease that has required systemic treatment in the past 2 years

Has active infection requiring systemic therapy

HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease

Has active inflammatory bowel disease requiring immunosuppressive medication or previous clear history of inflammatory bowel disease

Has known history of, or active, neurologic paraneoplastic syndrome

Has history of allogeneic tissue/solid organ transplant

Have not adequately recovered from major surgery or have ongoing surgical complications

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Lexington?

Yes, this clinical trial (NCT06780085) has an active research site in Lexington, KY that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Non-small Cell Lung Cancer Treatment Options in Lexington, KY

If you're searching for non-small cell lung cancer treatment options in Lexington, KY, this clinical trial (NCT06780085) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Lexington research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced non-small cell lung cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all non-small cell lung cancer clinical trials near you to find additional studies recruiting in your area.

Non-small Cell Lung Cancer Clinical Trial in Lexington, KY

Expert Care in Lexington

IRB Approved

No-Cost Care

Apply for This Lexington Location

Why Participate?

Simple Process